ASCO 2024 | TARGET-HPV: HB-200, a HPV16-specific immunotherapy, in oropharyngeal cancer
Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses the Phase I TARGET-HPV dose escalation study (NCT05108870) of neoadjuvant HB-200 with chemotherapy in non-metastatic HPV16+ oropharyngeal cancer (OPC). HB-200, an arenavirus-based vector therapy, demonstrated safety and feasibility with an early efficacy signal, showing deep responses in a majority of patients. Responses were particularly notable in those treated with higher doses. The study highlights the potential of HB-200 with chemotherapy in the treatment of OPC, warranting further investigation in randomized Phase II trials. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Galectin Therapeutics; Privo Technologies
Consulting or Advisory Role – Astellas Pharma; Eisai; EMD Serono; Nanobiotix; Novartis; Regeneron; Vaccitech
Speakers’ Bureau – Coherus Biosciences
Research Funding – Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Hookipa Biotech (Inst); Purple Biotech (Inst)
